Quarterly reports.
Primary-source data on peptide pricing, search trends, regulation and vendor economics. Free to cite under CC-BY 4.0 attribution.
Q2 2026 · mid-quarter updatePublished 2026-04-22
April 2026 Interim Peptide Index Update
A mid-quarter supplement to the Q2 2026 Peptide Index, covering the three events that reshaped the category in the back half of April 2026: Bryan Johnson's public CJC-1295 + tirzepatide protocol, Amazon's $149/mo GLP-1 launch via One Medical, and Alex Karnal's 'trillion-dollar public-health revolution' thesis on Invest Like the Best.
Editorially reviewed — medical review pendingQ2 2026Published 2026-04-21
The Pepwizard Q2 2026 Peptide Index
The state of peptide search, pricing, and regulation — aggregated from Pepwizard's live price data, Google Trends, and public regulatory sources.
Editorially reviewed — medical review pending